Download full-text PDF |
Source |
---|
Front Med (Lausanne)
December 2024
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Introduction: Although rituximab is approved for several autoimmune diseases, no formal dose finding studies have been conducted. The amount of CD20+ cells differs significantly between autoimmune diseases and B-cell malignancies. Hence, dose requirements of anti-CD20 therapies may differ accordingly.
View Article and Find Full Text PDFCurr Res Transl Med
October 2024
Student Research Committee, Faculty of Medicine, Shahed University, Tehran, Iran.
Introduction: Toxoplasma gondii (T. gondii) infects all warm-blooded animals, including humans. Currently, no effective treatments exist to prevent the generation of chronic tissue cysts in infected hosts.
View Article and Find Full Text PDFTransfus Med Hemother
October 2024
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Zhonghua Xue Ye Xue Za Zhi
June 2024
Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China.
Autoimmune hemolytic anemia (AIHA) is characterized by the accelerated destruction of erythrocytes due to the presence of antibodies and/or complement that bind to antigens on erythrocytes. It can be subdivided into warm, cold or mixed AIHA based on the type of autoantibody and the optimal temperature of antigen-antibody reaction. Glucocorticoid with or without rituximab is the first-line treatment of warm AIHA (wAIHA), and splenectomy was once the preferred second-line treatment for relapsed or refractory wAIHA.
View Article and Find Full Text PDFBiomedicines
July 2024
Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Although rituximab is not specifically approved for the treatment of warm autoimmune hemolytic anemia (WAIHA), the First International Consensus Group recommends considering its use as part of the initial therapy for patients with severe disease and as a second-line therapy for primary WAIHA. Some patients do not respond to rituximab, and relapses are common. These relapses are associated with elevated B-cell-activating factor (BAFF) levels and the presence of quiescent long-lived plasma cells (LLPCs) in the spleen.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!